Our findings demonstrate that the deletion of miR‐525‐3p contributes to the aberrant expression of SEMG1, clinically involving in AZS and male infertility, which provides a potential therapeutic target for the treatment of male infertility and for male contraception. The gene discussed is SEMG1; the disease is male infertility.